W.L. Gore & Associates

Mitico specializes in advanced carbon capture solutions, utilizing a patented granulated metal carbonate sorption technology developed at Caltech. This innovative approach effectively captures over 95% of carbon dioxide emissions from post-combustion sources, such as gas-fired power plants, boilers, and waste-to-energy facilities. By providing carbon capture, utilization, and storage (CCUS) as a service, Mitico enables clients to significantly reduce their carbon emissions at a lower cost compared to conventional methods. The company's technology aims to facilitate mass mitigation of carbon emissions, making it an essential partner for industries seeking to address environmental challenges and transition towards more sustainable practices.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

InnAVasc Medical, Inc., established in 2013 and headquartered in Durham, North Carolina, specializes in the design and development of medical devices for vascular access in hemodialysis. The company's primary product, the Bullet Proof Vascular Access Graft, is an arteriovenous graft featuring two multilayer cannulation chambers, engineered to resist posterior and sidewall needle penetration and injury, thereby enhancing the safety and longevity of vascular access for hemodialysis patients.

PhysioLogic Devices, Inc. is a company based in Alpine, California, established in 2013, that specializes in the development of innovative implantable products aimed at improving the management of diabetes. The company focuses on creating advanced devices, including an implantable insulin pump and a glucose sensor, which work together to fully automate glucose control. By delivering insulin directly to the intraperitoneal space for uptake by the liver, these products aim to normalize glucose physiology, offering patients with Type 1 diabetes a significant improvement in their quality of life by alleviating the burdens associated with traditional insulin therapy.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Quellan, Inc. specializes in the design, development, and marketing of analog signal processing and radio frequency noise cancellation integrated circuits (IC) aimed at automotive, computing, data center, storage, consumer electronics, and wireless markets. The company offers a range of products, including noise cancellers that detect unwanted noise and generate an opposing signal, system developer kits for mobile television and GPS applications, quad and single lane extenders that ensure analog signal integrity in data center equipment, as well as evaluation boards, cable modules, and active cables. Quellan's technologies are utilized in various applications such as active cables, line cards, and backplanes in data centers, as well as in wireless technologies like global positioning systems and mobile television. Founded in 2001 and headquartered in Santa Clara, California, Quellan operates as a subsidiary of Intersil Corp as of August 2009.